MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory ...
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5BOCA RATON, ...
Natural killer cells offer hope for hard-to-treat pediatric sarcomas
University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...